Daridorexant (insomnia)



  • Active Substance: Daridorexant 
  • Name: Quviviq®
  • Therapeutic area: Insomnia
  • Pharmaceutical company: Idorsia Pharmaceuticals Germany GmbH


Time table:

  • Start: 15.11.2022
  • Publication of assessment: 15.02.2023
  • End of public hearing: 09.03.2023
  • Final decision by G-BA: middle of May 2023


Comparative therapy:

  • Short-term drug therapy with short-acting benzodiazepines or nonbenzodiazepine receptor agonists, followed by best-supportive care
  • (best supportive care is defined as the therapy that provides the best possible supportive treatment optimized for the individual patient to alleviate symptoms and improve quality of life.)